What is Manifold Bio?
Manifold Bio operates at the intersection of synthetic biology and data-driven drug discovery. The company's core mission is to harness the power of multiplexed measurement to accelerate the development of life-saving therapeutics. By integrating high-throughput experimental platforms with sophisticated computational models, Manifold Bio addresses the inherent complexities of biological systems. This approach allows for more precise engineering of protein-based medicines, effectively reducing the time and cost associated with traditional drug development cycles. As a leader in the next generation of biotech, the company is transforming how researchers identify and optimize therapeutic candidates, moving beyond linear testing methods toward a more holistic, data-rich paradigm.
How much funding has Manifold Bio raised?
Manifold Bio has raised a total of $45.4M across 2 funding rounds:
Angel/Seed
$5.4M
Series A
$40M
Angel/Seed (2020): $5.4M with participation from Fifty Years, GETTYLAB, Allston Venture Fund, and Playground Global
Series A (2022): $40M led by FPV Ventures, Tencent, Playground Global, Fifty Years, Section 32, Horizons Ventures, and Triatomic Capital
Key Investors in Manifold Bio
Fifty Years
Fifty Years is a pre-seed and seed focused venture capital firm that supports founders leveraging technology to address significant global challenges such as climate change, disease, and malnutrition.
Playground Global
Playground Global invests in founders harnessing frontier technologies to build transformational businesses with multi-generational impact across life sciences and artificial intelligence.
Tencent
Tencent is a global technology company that invests in technology innovation and supports developers through a broad ecosystem of digital platforms and enterprise solutions.
What's next for Manifold Bio?
With the recent infusion of capital, Manifold Bio is well-positioned to scale its proprietary platform and expand its pipeline of therapeutic candidates. The company's strategic roadmap focuses on deepening its computational capabilities and enhancing its laboratory infrastructure to support larger-scale multiplexed experiments. By continuing to attract high-caliber investment, Manifold Bio is set to transition from a research-intensive startup to a clinical-stage powerhouse. Future growth will likely involve strategic partnerships with pharmaceutical incumbents and the further refinement of its machine learning algorithms to predict biological outcomes with unprecedented accuracy, ultimately aiming to bring novel treatments to market with greater efficiency.
See full Manifold Bio company page
